Viva Biotech (01873) Schedules 30 Mar 2026 Board Meeting to Approve FY 2025 Results and Final Dividend Proposal

Bulletin Express

Mar 18

Viva Biotech Holdings (Stock Code: 01873) has announced that its board of directors will convene on 30 March 2026. The meeting will focus on three core agenda items:

1. Reviewing and approving the consolidated results of the company and its subsidiaries for the financial year ended 31 December 2025.

2. Authorising the publication of the FY 2025 annual results.

3. Considering a recommendation for the payment of a final dividend, if any.

The board currently comprises seven members: three Executive Directors—Mr. Mao Chen Cheney (Chairman and Chief Executive Officer), Mr. Wu Ying and Mr. Ren Delin; one Non-executive Director—Mr. Wu Yuting; and three Independent Non-executive Directors—Mr. Fu Lei, Ms. Li Xiangrong and Mr. Wang Haiguang.

The announcement was signed by Chairman and CEO Mr. Mao Chen Cheney and released in Hong Kong on 18 March 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1107739607"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1107739607\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1107739607?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-18 16:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1107739607","market":"us","top_or_hot":-1,"title":"Viva Biotech (01873) Schedules 30 Mar 2026 Board Meeting to Approve FY 2025 Results and Final Dividend Proposal","media":"Bulletin Express","content":"<p>Viva Biotech Holdings (Stock Code: 01873) has announced that its board of directors will convene on 30 March 2026. The meeting will focus on three core agenda items:</p>\n<p>1. Reviewing and approving the consolidated results of the company and its subsidiaries for the financial year ended 31 December 2025.</p>\n<p>2. Authorising the publication of the FY 2025 annual results.</p>\n<p>3. Considering a recommendation for the payment of a final dividend, if any.</p>\n<p>The board currently comprises seven members: three Executive Directors—Mr. Mao Chen Cheney (Chairman and Chief Executive Officer), Mr. Wu Ying and Mr. Ren Delin; one Non-executive Director—Mr. Wu Yuting; and three Independent Non-executive Directors—Mr. Fu Lei, Ms. Li Xiangrong and Mr. Wang Haiguang.</p>\n<p>The announcement was signed by Chairman and CEO Mr. Mao Chen Cheney and released in Hong Kong on 18 March 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Viva Biotech (01873) Schedules 30 Mar 2026 Board Meeting to Approve FY 2025 Results and Final Dividend Proposal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nViva Biotech (01873) Schedules 30 Mar 2026 Board Meeting to Approve FY 2025 Results and Final Dividend Proposal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-18 16:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Viva Biotech Holdings (Stock Code: 01873) has announced that its board of directors will convene on 30 March 2026. The meeting will focus on three core agenda items:</p>\n<p>1. Reviewing and approving the consolidated results of the company and its subsidiaries for the financial year ended 31 December 2025.</p>\n<p>2. Authorising the publication of the FY 2025 annual results.</p>\n<p>3. Considering a recommendation for the payment of a final dividend, if any.</p>\n<p>The board currently comprises seven members: three Executive Directors—Mr. Mao Chen Cheney (Chairman and Chief Executive Officer), Mr. Wu Ying and Mr. Ren Delin; one Non-executive Director—Mr. Wu Yuting; and three Independent Non-executive Directors—Mr. Fu Lei, Ms. Li Xiangrong and Mr. Wang Haiguang.</p>\n<p>The announcement was signed by Chairman and CEO Mr. Mao Chen Cheney and released in Hong Kong on 18 March 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01873","symbol_name":"维亚生物","start_time":0,"source_url":"","article_id":"1107739607","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1107739607","pubTimestamp":1773823256,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Viva Biotech Holdings (Stock Code: 01873) has announced that its board of directors will convene on 30 March 2026. The meeting will focus on three core agenda items: 1. Reviewing and approving the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01873":"维亚生物"},"translate_title":"维亚生物(01873)定于2026年3月30日召开董事会批准2025财年业绩及末期股息建议","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01873":1},"content_text":"Viva Biotech Holdings (Stock Code: 01873) has announced that its board of directors will convene on 30 March 2026. The meeting will focus on three core agenda items:\n1. Reviewing and approving the consolidated results of the company and its subsidiaries for the financial year ended 31 December 2025.\n2. Authorising the publication of the FY 2025 annual results.\n3. Considering a recommendation for the payment of a final dividend, if any.\nThe board currently comprises seven members: three Executive Directors—Mr. Mao Chen Cheney (Chairman and Chief Executive Officer), Mr. Wu Ying and Mr. Ren Delin; one Non-executive Director—Mr. Wu Yuting; and three Independent Non-executive Directors—Mr. Fu Lei, Ms. Li Xiangrong and Mr. Wang Haiguang.\nThe announcement was signed by Chairman and CEO Mr. Mao Chen Cheney and released in Hong Kong on 18 March 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"executive,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}